Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hofheinz, Ralf
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients	Completed	3	430	Europe	Ramucirumab, TAS 102	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH	Colorectal Cancer	07/24	07/24
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer	Completed	2	124	Europe	Aflibercept + mLV5FU2, mFOLFOX7	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi	Colorectal Cancer	02/24	02/24
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma	Active, not recruiting	1/2	56	Europe	Sacituzumab govitecan, Trodelvy	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences	Esophagogastric Adenocarcinoma	02/27	03/27
PARAGON, NCT04119362: Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer	Completed	N/A	469	Europe	Quality of live questionnaires, Optional translational project	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Celgene	Pancreatic Adenocarcinoma	06/23	06/23